{"id":499789,"date":"2020-08-01T00:00:00","date_gmt":"2020-07-30T18:36:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=499789"},"modified":"2020-07-30T18:36:02","modified_gmt":"2020-07-30T18:36:02","slug":"attentiondeficithyperactivity-disorder-adhd-pipeline-assessment-key-companies-and-emerging-drugs","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/attentiondeficithyperactivity-disorder-adhd-pipeline-assessment-key-companies-and-emerging-drugs_499789.html","title":{"rendered":"Attention-Deficit\/Hyperactivity Disorder (ADHD) Pipeline Assessment, Key Companies And Emerging Drugs"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Attention-Deficit\/Hyperactivity Disorder (ADHD) Pipeline Assessment, Key Companies And Emerging Drugs\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Attention-Deficit\/Hyperactivity Disorder (ADHD) Pipeline Assessment, Key Companies And Emerging Drugs\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Attention-Deficit\/Hyperactivity Disorder (ADHD) Pipeline Insight, 2020&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Attention-Deficit\/Hyperactivity Disorder (ADHD) market. <\/p>\n<\/div>\n<p style=\"text-align: justify;\">The DelveInsight&#8217;s&nbsp;Attention-Deficit\/Hyperactivity Disorder (ADHD) Pipeline report provides detailed analysis of&nbsp;<strong>commercial assessment and clinical assessment of the Attention-Deficit\/Hyperactivity Disorder (ADHD) pipeline products<\/strong> from the pre-clinical developmental phase to the marketed phase. <br \/>In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Attention-Deficit\/Hyperactivity Disorder (ADHD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get FREE sample copy at:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/attention-deficit-hyperactivity-disorder-adhd-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/attention-deficit-hyperactivity-disorder-adhd-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"attention-deficit-hyperactivity-disorder-adhd-pipeline-insight\" src=\"https:\/\/www.abnewswire.com\/uploads\/821208744c8bd9d95a685d112b3a42ef.jpg\" alt=\"attention-deficit-hyperactivity-disorder-adhd-pipeline-insight\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the leading Companies worldwide, are coming up with novel therapeutic approaches that can entirely change the treatment landscape of Attention Deficit Hyperactivity Disorder (ADHD) in the coming years.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key pharma players in the Attention-deficit\/hyperactivity disorder (ADHD) market.<\/strong><br \/>KemPharm<br \/>Supernus Pharmaceuticals<br \/>Sumitomo Dainippon Pharma<br \/>Otsuka Pharmaceuticals<br \/>AEVI Genomic Medicine<br \/>Amarantus Bioscience<br \/>NLS Pharma<br \/>RespireRx Pharmaceuticals <br \/>And many more<\/p>\n<p style=\"text-align: justify;\"><strong>Drugs Covered<\/strong><br \/>Dasotraline<br \/>SPN-812<br \/>centanafadine<br \/>KP415<br \/>KP484<br \/>AEVI-001<br \/>Eltoprazine<br \/>NLS-1 mazindol CR <br \/>CX717<br \/>And many more<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/attention-deficit-hyperactivity-disorder-adhd-pipeline-insight\" target=\"_blank\"><strong>The Attention-Deficit\/Hyperactivity Disorder (ADHD) of Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report provides insights into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the treatment of Attention-Deficit\/Hyperactivity Disorder (ADHD) with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Attention-Deficit\/Hyperactivity Disorder (ADHD) treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Attention-Deficit\/Hyperactivity Disorder (ADHD) key players<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Attention-Deficit\/Hyperactivity Disorder (ADHD) market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The <strong>Attention-Deficit\/Hyperactivity Disorder (ADHD) Report<\/strong> provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Attention-Deficit\/Hyperactivity Disorder (ADHD) across the complete product development cycle, including all clinical and nonclinical stages.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It comprises of detailed profiles of Attention-Deficit\/Hyperactivity Disorder (ADHD) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed <strong>Attention-Deficit\/Hyperactivity Disorder (ADHD) research and development progress and trial details<\/strong>, results wherever available, are also included in the pipeline study.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage of dormant and discontinued pipeline projects along with the reasons if available across Attention-Deficit\/Hyperactivity Disorder (ADHD).<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">A better understanding of disease pathogenesis contributing to the development of <strong>novel therapeutics for Attention-Deficit\/Hyperactivity Disorder (ADHD)<\/strong>.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">In the coming years, the Attention-Deficit\/Hyperactivity Disorder (ADHD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The companies and academics that are working to assess challenges and seek opportunities that could influence Attention-Deficit\/Hyperactivity Disorder (ADHD) R&amp;D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">A detailed portfolio of major pharma players who are involved in fueling the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/attention-deficit-hyperactivity-disorder-adhd-pipeline-insight\" target=\"_blank\"><strong>Attention-Deficit\/Hyperactivity Disorder (ADHD) treatment market<\/strong><\/a>. Several potential therapies for Attention-Deficit\/Hyperactivity Disorder (ADHD) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Attention-Deficit\/Hyperactivity Disorder (ADHD) market size in the coming years.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Attention-Deficit\/Hyperactivity Disorder (ADHD)) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Attention-Deficit\/Hyperactivity Disorder (ADHD)&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Attention-Deficit\/Hyperactivity Disorder (ADHD) Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Attention-Deficit\/Hyperactivity Disorder (ADHD) &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Attention-Deficit\/Hyperactivity Disorder (ADHD) Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Attention-Deficit\/Hyperactivity Disorder (ADHD) Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Attention-Deficit\/Hyperactivity Disorder (ADHD) Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Attention-Deficit\/Hyperactivity Disorder (ADHD) Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attention-Deficit\/Hyperactivity Disorder (ADHD) Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Attention-Deficit\/Hyperactivity Disorder (ADHD) Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Attention-Deficit\/Hyperactivity Disorder (ADHD) Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Attention-Deficit\/Hyperactivity Disorder (ADHD) Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Attention-Deficit\/Hyperactivity Disorder (ADHD) Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/attention-deficit-hyperactivity-disorder-adhd-market\">Attention-deficit\/hyperactivity disorder (ADHD) Market Insight, Epidemiology and Market Forecast -2030<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;Attention-deficit\/hyperactivity disorder (ADHD) Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Attention-deficit\/hyperactivity disorder (ADHD), historical and forecasted epidemiology as well as the Attention-deficit\/hyperactivity disorder (ADHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/attention-deficit-hyperactivity-disorder-adhd-epidemiology-forecast\"><span>Attention-deficit\/hyperactivity disorder (ADHD) Epidemiology Forecast to 2030<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s Attention-deficit\/hyperactivity disorder (ADHD) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Attention-deficit\/hyperactivity disorder (ADHD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Anuj Rawat<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=attentiondeficithyperactivity-disorder-adhd-pipeline-assessment-key-companies-and-emerging-drugs\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=attentiondeficithyperactivity-disorder-adhd-pipeline-assessment-key-companies-and-emerging-drugs\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research &#8220;Attention-Deficit\/Hyperactivity Disorder (ADHD) Pipeline Insight, 2020&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Attention-Deficit\/Hyperactivity Disorder (ADHD) market. The DelveInsight&#8217;s&nbsp;Attention-Deficit\/Hyperactivity Disorder (ADHD) Pipeline report provides detailed analysis of&nbsp;commercial assessment &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/attentiondeficithyperactivity-disorder-adhd-pipeline-assessment-key-companies-and-emerging-drugs_499789.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-499789","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=499789"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499789\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=499789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=499789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=499789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}